PEIJIA-B (09996) rose more than 7% in afternoon trading. At the time of writing, the stock was up 6.87% to HK$6.07, with a turnover of HK$6.103 million. The company previously released its annual results, reporting revenue of RMB 713 million, a year-on-year increase of 15.82%. During the period, revenue from TAVR-related products grew 11.6% to RMB 290 million, while revenue from neurointervention products increased 18.9% to RMB 423 million, with segment profit rising 86.6% to RMB 97.2 million. An institutional research report noted that looking ahead to 2026, the TAVR segment is expected to benefit from volume growth following national price negotiations and the commercialization of the regurgitation valve TaurusTrio. The neurointervention segment, with coils providing stable cash flow and DCwire micro-guidewires receiving FDA approval, is set to contribute overseas revenue. It is estimated that the company's TAVR segment revenue could grow by 30% in 2026, while the neurointervention business is expected to maintain a steady growth rate of 15-20%. The group aims to achieve breakeven within the year. With the third-generation long-lasting valve TaurusNXT and the mitral valve repair system GeminiOne TEER in the registration phase and multiple TMV/TTV clinical pipelines advancing steadily, a "Buy" rating has been maintained.